Real-world safety of palbociclib in breast cancer patients in the United States: A new user cohort study

There is limited real-world safety information on palbociclib for treatment of advanced stage HR+/ HER2- breast cancer. This real-world study found increased risks of several adverse events identified in clinical trials, including neutropenia, leukopenia, and thrombocytopenia, but no increased risk of serious infections or pulmonary embolism when comparing new users of palbociclib-fulvestrant to fulvestrant monotherapy.